Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 84. (Canceled)

85. (Currently amended) A method of ~~inhibiting~~ reducing mucus hypersecretion in the airways of a subject in need of such treatment comprising administration to the airways of said subject a pharmaceutical formulation comprising a mucus-inhibitory amount of a N-terminal myristoylated peptide ~~fragment of the N-terminal region of the MARCKS protein~~ consisting of an amino acid sequence of from ~~about~~ 10 to ~~about~~ 50 contiguous amino acids that is identical to a contiguous sequence of amino acids beginning ~~from~~ at the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4, wherein said peptide ~~fragment inhibits~~ reduces MARCKS protein-related mucus hypersecretion, and whereby mucus hypersecretion in said airways is reduced compared to that which would occur in the absence of said peptide.

86. (Previously presented) The method according to claim 85, wherein said subject suffers from a disease in which airway mucus hypersecretion is a dominant clinical finding.

87. (Previously presented) The method according to claim 86, wherein said disease is a pulmonary or respiratory disease associated with mucus hypersecretion.

88. (Previously presented) The method according to claim 85, further comprising removal of retained mucus secretions from the airways of said mammalian subject prior to administering said peptide.

89. (Previously presented) The method according to claim 85, wherein said administration is by inhalation.

90. (Canceled)

91. (Currently amended) A pharmaceutical formulation comprising a N-terminal myristoylated peptide ~~fragment of the N-terminal region of the MARCKS protein~~ consisting of an amino acid sequence of from ~~about~~ 10 to ~~about~~ 50 contiguous amino acids that is identical to a contiguous sequence of amino acids beginning ~~from~~ at the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO: 4, wherein said peptide ~~fragment inhibits~~ reduces MARCKS protein-related mucus hypersecretion, and a pharmaceutically acceptable carrier.

92. (Previously presented) The pharmaceutical formulation according to claim 91, wherein said formulation is aerosolized.

93. (Previously presented) The pharmaceutical formulation according to claim 91, wherein said peptide is contained within liposomes.

94. - 100. (Canceled)

101. (Currently amended) A method of ~~inhibiting~~ reducing mucus hypersecretion in the airways of a subject in need of such treatment comprising administration to the airways of said subject a pharmaceutical formulation comprising a mucus-inhibitory amount of a MANS peptide, wherein said MANS peptide ~~inhibits~~ reduces MARCKS protein-related mucus hypersecretion, and whereby mucus hypersecretion in said airways is reduced compared to that which would occur in the absence of said MANS peptide, wherein said MANS peptide consists of a N-terminal myristoylated peptide of SEQ ID NO:1.

102. (Previously presented) The method according to claim 101, wherein said subject suffers from a disease in which airway mucus hypersecretion is a dominant clinical finding.

103. (Previously presented) The method according to claim 102, wherein said disease is a pulmonary or respiratory disease associated with mucus hypersecretion.

104. (Previously presented) The method according to claim 101, further comprising removal of retained mucus secretions from the airways of said mammalian subject prior to administering said peptide.

105. (Previously presented) The method according to claim 101, wherein said administration is by inhalation.

106. (Canceled)

107. (Currently amended) A pharmaceutical formulation comprising a MANS peptide, wherein said MANS peptide ~~inhibits~~ reduces MARCKS protein-related mucus hypersecretion, and a pharmaceutically acceptable carrier, wherein said MANS peptide consists of a N-terminal myristoylated peptide of SEQ ID NO:1.

108. (Previously presented) The pharmaceutical formulation according to claim 107, wherein said formulation is aerosolized.

109. (Previously presented) The pharmaceutical formulation according to claim 107, wherein said MANS peptide is contained within liposomes.

110. (Canceled)

111. (Currently amended) The method according to claim ~~87~~ 86, wherein said disease is asthma ~~selected from the group consisting of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, emphysema, pneumonia, influenza, rhinitis and the common cold~~.

112. (Currently amended) The method according to claim ~~103~~ 102, wherein said disease is asthma ~~selected from the group consisting of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, emphysema, pneumonia, influenza, rhinitis and the common cold~~.

113. – 115. (Canceled)

116. (New) The method according to claim 85, wherein said N-terminal myristoylated peptide consists of at least 15 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

117. (New) The pharmaceutical formulation according to claim 91, wherein said N-terminal myristoylated peptide consists of at least 15 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

118. (New) The method according to claim 85, wherein said N-terminal myristoylated peptide consists of at least 20 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

119. (New) The pharmaceutical formulation according to claim 91, wherein said N-terminal myristoylated peptide consists of at least 20 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

120. (New) The method according to claim 85, wherein said N-terminal myristoylated peptide consists of at least 25 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

121. (New) The pharmaceutical formulation according to claim 91, wherein said N-terminal myristoylated peptide consists of at least 25 contiguous amino acids beginning from the N-terminal glycine residue of the MARCKS protein as shown in SEQ ID NO:4.

122. (New) The method according to claim 86, wherein said disease is chronic obstructive pulmonary disease.

123. (New) The method according to claim 122, wherein said chronic obstructive pulmonary disease is bronchitis or emphysema.

124. (New) The method according to claim 102, wherein said disease is chronic obstructive pulmonary disease.

125. (New) The method according to claim 124, wherein said chronic obstructive pulmonary disease is bronchitis or emphysema.

126. (New) The method according to claim 86, wherein said disease is cystic fibrosis.

127. (New) The method according to claim 102, wherein said disease is cystic fibrosis.

128. (New) The method according to claim 86, wherein said disease is bronchiectasis.

129. (New) The method according to claim 102, wherein said disease is bronchiectasis.

130. (New) The method according to claim 86, wherein said disease is pneumonia.

131. (New) The method according to claim 102, wherein said disease is pneumonia.

132. (New) The method according to claim 86, wherein said disease is influenza.

133. (New) The method according to claim 102, wherein said disease is influenza.

134 (New) The method according to claim 86, wherein said disease is rhinitis or the common cold.

135. (New) The method according to claim 102, wherein said disease is rhinitis or the common cold.